Overview

A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)

Status:
Terminated

Trial end date:
2012-08-24

Target enrollment:

Participant gender:

Summary

The primary purpose of the study is to evaluate the safety and PK profile of CC-930 in idiopathic pulmonary fibrosis patients.

Phase:

Phase 2

Details

Lead Sponsor:

Celgene
Celgene Corporation